CompletedNCT02363738

12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression

Medication studyAges 18–65Canada + United StatesBipolarity

The study in practice

Understand this study

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations: Palo Alto, United States · Toronto, CanadaSee all locations and recruitment
Activities: Medication described in the protocol · Placebo comparator
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateSeptember 2015

Recruitment status: Completed
Enrollment listed in the registry: 60
Sponsor: University Health Network, Toronto
Sponsor type: University
Study type: Drug
Intervention type: Medication / drug, OTHER
Study phase: Phase 2
Locations: United States, Canada
Age range: From 18 Years to 65 Years
Official registry ID: NCT02363738
Official title: Show the full official title
A Multisite, Fixed Dose, Randomized, Double-Blind, Placebo-Controlled 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for the Treatment of Bipolar I/II Depression

Completed

Palo Alto, United States · Toronto, Canada

FAQ

Who is behind this study?

The study sponsor is University Health Network, Toronto, a university.

Did this study involve medication?

Yes. The study involved medication, including Infliximab.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.